Johnson & Johnson Receives European Commission Approval for Carvykti in Multiple Myeloma

Johnson & Johnson today announced that the European Commission has approved Carvykti (ciltacabtagene autoleucel) for the treatment of adults with relapsed or refractory multiple myeloma who have received at least three prior therapies in the European Union. The approval was based on results from the CARTITUDE-1 trial, which demonstrated an overall response rate of 98% and a complete response rate of 78%. This approval makes Carvykti available to multiple myeloma patients across all EU member states. J&J is committed to ensuring broad patient access to Carvykti in Europe.